Lexicon Pharmaceuticals (LXRX) CFO logs RSU conversion and tax share withholding

Rhea-AI Filing Summary

Lexicon Pharmaceuticals SVP & CFO Scott M. Coiante reported equity award activity. On February 28, he acquired 160,237 shares of common stock through the exercise of restricted stock units at no cost, while 54,881 shares were withheld by the company to cover tax obligations. Following these transactions, he directly owns 105,356 shares of common stock and 320,473 restricted stock units, each representing the right to receive one share as they vest over time.

Insider Trade Summary

160,237 shares exercised/converted

Mixed 3 txns

Insider Coiante Scott M

Role SVP, Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	160,237	$0.00	--
Exercise	Common Stock	160,237	$0.00	--
Tax Withholding	Common Stock	54,881	$1.47	$81K

Holdings After Transaction: Restricted Stock Units — 320,473 shares (Direct); Common Stock — 160,237 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of common stock. Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coiante Scott M

(Last) (First) (Middle)

2445 TECHNOLOGY FOREST BLVD

11TH FLOOR

(Street)

SPRING TX 77381

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEXICON PHARMACEUTICALS, INC. [ LXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/28/2026		M		160,237	A	(1)	160,237	D
Common Stock	02/28/2026		F(2)		54,881	D	$1.47	105,356	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/28/2026		M			160,237	(3)	(3)	Common Stock	160,237	(1)	320,473	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock.

2. Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.

3. Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.

	/s/ Scott M. Coiante	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did LXRX CFO Scott Coiante report on February 28?

Scott Coiante reported exercising 160,237 restricted stock units into common shares on February 28. The company simultaneously withheld 54,881 common shares to satisfy his tax obligations, leaving him with 105,356 common shares and 320,473 unvested restricted stock units held directly.

How many Lexicon Pharmaceuticals (LXRX) shares does the CFO own after this Form 4?

After these transactions, the CFO directly owns 105,356 shares of common stock. He also holds 320,473 restricted stock units, each representing a contingent right to receive one share of common stock as they vest according to the award’s vesting schedule.

What type of equity award did the LXRX CFO exercise in this Form 4 filing?

The CFO exercised restricted stock units, converting 160,237 units into an equal number of common shares at a price of $0.00 per share. Each restricted stock unit represents a contingent right to receive one share of common stock when vesting conditions are satisfied.

Why were 54,881 LXRX shares disposed of in the CFO’s Form 4?

The 54,881 shares reported as a disposition were withheld by the company to cover the CFO’s tax withholding obligations related to the equity award. This tax-withholding disposition is reflected with a transaction code “F” and is not an open-market sale of shares.

How do the LXRX restricted stock units reported by the CFO vest over time?

The restricted stock units vest in three equal annual installments. One-third of the shares subject to the restricted stock units vest on February 28 of each of the three years following the year of grant, assuming the applicable vesting conditions continue to be met.